Popular on Rezul
- Robert DeMaio, Phinge CEO to Speak at 30th IIPLA 2026 on Securing IP, User Data & Digital Sovereignty via Verified App-less Tech. Attend the Live Q&A! - 195
- JiT Home Buyers Expands Local Presence to 18 Real Estate Markets Across the United States - 169
- Sales Blueprint Architect Launches, Helping Sales Professionals, Business Owners, and Consultants Close More Business With AI - 124
- CasaPerks and CredHub Partner to Help the Multifamily Industry Strengthen Resident Activation Through Credit-Building Rewards - 117
- DuoKey launches the World's First Agentic Crypto Agility Platform
- PulteGroup expands Northeast Florida presence with Oakmere coming soon to Mandarin
- Break the Resume Mold: Career Valet Changes How Executives Hunt for Jobs
- Supreme Garage Door Repair Redirects Marketing Dollars Into North Texas Communities
- Dueño a Dueño Launches Bilingual Owner-Financing Marketplace to Help Memphis Family
- Titan Pressure Washing Demonstrates How to Clean Paver Driveways Without Sacrificing Landscaping
Similar on Rezul
- Inglewood Associates and Gordon Brothers Provide Update on Sale Process for 925 Euclid Avenue in Cleveland
- Bank Statement Loans Up to $30 Million: Lendmire Announces High-Net-Worth Financing
- Ragin' Cajun Announces New Cheeseburger Seasoning on National Cheeseburger Day
- Warrant Activity, AVERSA™ Progress and a Potentially Transformative Fall Take Center Stage: Nutriband Inc. (N A S D A Q: NTRB)
- Future Intelligence Think Tank Surpasses 1,000 Members Exploring Human and Artificial Intelligence
- Gary Bernstein Expands Media Leadership Role With Senior Strategic Advisor Appointment To Blacksun Private Equity
- Can Government Operate Better Through Innovation?
- Infinity Infusion Solutions Named Finalist for D Magazine's D CEO 2026 Excellence in Healthcare Awards
- Building a Diversified Healthcare Platform as Exosome Science, Telehealth, Diagnostics & Strategic Acquisitions Converge: NexTel Medical (OTCID: MAJI)
- Retell AI White Label Platform for Agencies Launched by VoiceAIWrapper, With Branded Client Portals and No Per-Minute Markup
Arcus Biosciences Announces New Employment Inducement Grants
Rezul News/10608101
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that the Compensation Committee of the Company's Board of Directors granted seven new employees options to purchase a total of 11,400 shares of the Company's common stock at an exercise price per share of $27.17, which was the closing price on November 23, 2022, and restricted stock units to acquire a total of 5,700 shares of the Company's common stock. The equity awards were granted pursuant to the Company's 2020 Inducement Plan, which was approved by the Company's Board of Directors in January 2020 pursuant to the "inducement exception" under NYSE Listed Company Manual Rule 303A.08.
About Arcus Biosciences
Arcus Biosciences is a clinical-stage, global biopharmaceutical company developing differentiated molecules and combination medicines for people with cancer. In partnership with industry partners, patients and physicians around the world, Arcus is expediting the development of first- or best-in-class medicines against well characterized biology and pathways and studying novel, biology-driven combinations that have the potential to help people with cancer live longer. Founded in 2015, the company has expedited the development of six investigational medicines into clinical studies, including new combination approaches that target TIGIT, PD-1, the adenosine axis (CD73 and dual A2a/A2b) and most recently, HIF-2alfa. For more information about Arcus Biosciences' clinical and pre-clinical programs, please visit www.arcusbio.com or follow us on Twitter.
More on Rezul News
Inducement PR
Source: Arcus Biosciences
Contacts
Investor and Media Inquiries:
Holli Kolkey
VP of Corporate Communications
(650) 922-1269
hkolkey@arcusbio.com
About Arcus Biosciences
Arcus Biosciences is a clinical-stage, global biopharmaceutical company developing differentiated molecules and combination medicines for people with cancer. In partnership with industry partners, patients and physicians around the world, Arcus is expediting the development of first- or best-in-class medicines against well characterized biology and pathways and studying novel, biology-driven combinations that have the potential to help people with cancer live longer. Founded in 2015, the company has expedited the development of six investigational medicines into clinical studies, including new combination approaches that target TIGIT, PD-1, the adenosine axis (CD73 and dual A2a/A2b) and most recently, HIF-2alfa. For more information about Arcus Biosciences' clinical and pre-clinical programs, please visit www.arcusbio.com or follow us on Twitter.
More on Rezul News
- NYC Big Book Award Celebrates 10th Anniversary with Announcement of 2026 Winners
- Regional Magazines Shine at IRMA Awards
- ConnectNeighbors.com Launches Free Nationwide REALTOR® Referral Search Service
- Historic Abington Park Estate Comes to Market for Its Next Chapter
- Matt Zavala of Zavala Law, PC Selected to the 2027 Super Lawyers List
Inducement PR
Source: Arcus Biosciences
Contacts
Investor and Media Inquiries:
Holli Kolkey
VP of Corporate Communications
(650) 922-1269
hkolkey@arcusbio.com
Filed Under: Business
0 Comments
Latest on Rezul News
- Gary Bernstein Expands Media Leadership Role With Senior Strategic Advisor Appointment To Blacksun Private Equity
- Headline: House of Nova Paints Every Face in Gold at New York Fashion Week
- Can Government Operate Better Through Innovation?
- MAD Properties Group's Give Back Program Returns Commission Dollars to Military Buyers and Sellers
- Pinnacle Home Improvements Named Best Siding Company in Atlanta by My Home Improvement Magazine
- Michael H. Kaplan Advocates for Seriously Injured Colorado Workers Who Need In-Home Care
- David Weekley Homes Readies 156 Acres for New 55 + Community to Debut in McDonough in Fall 2026
- Corner Property Management AAMC Partners with Georgetown Mews for Enhanced Community Operations
- From The Good Life Show to The American Dream: Shaun Alston's Story Comes Full Circle
- Infinity Infusion Solutions Named Finalist for D Magazine's D CEO 2026 Excellence in Healthcare Awards
- Distinctive Domain Receives 2025 Custom Home Remodel Transformation Award: Martinsville Renovation
- Kids Art Day Brings Creativity, Smiles, and Community Together at Colony Ridge
- Why Our Motto Is "Building a Future Together"
- Andrew-Thomas Contractors Launches Enhanced Safety Bollards Resource for Denver Metro Businesses
- Mesa West Capital Originates $27 Million Loan for Seattle Apartment Acquisition
- Canadian Tint Expo 2027: Why Every Window Tinter Should Compete in Niagara Falls on April 3rd & 4th
- The Drywall Helper Introduces a Versatile Approach to Measuring and Supporting Drywall
- InvisoScreen™ Introduces a New Approach to Window Screening
- Mach One Reports Launches Voice-First Software That Builds Inspection Reports On Site
- Building a Diversified Healthcare Platform as Exosome Science, Telehealth, Diagnostics & Strategic Acquisitions Converge: NexTel Medical (OTCID: MAJI)